Skip directly to site content Skip directly to search


Español  Other Languages


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search
		×
			Vaccines site
			Vaccines site
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


Advisory Committee on Immunization Practices (ACIP)








Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) for HPV Vaccine for Males						Print
																Related Pages
										Printer friendly version of this page [9 pages]
Methods for GRADE: HPV vaccine for Males
Evidence of benefits, harms, values and preferences, and cost-effectiveness were reviewed in accordance with GRADE methods (Ahmed F, et al). The primary policy question was “Should HPV4 be recommended for routine use in 11-12 year old boys.” The benefits considered included prevention of genital warts, anal intraepithelial neoplasia (AIN), and anal cancer. The harms considered included serious adverse events (SAE), venous thromboembolism (VTE), syncope, and anaphylaxis. Data on efficacy were from a randomized clinical trial of HPV4 in males; data on adverse effects were from randomized clinical trials of HPV4 in males and females, and post-licensure studies of HPV4 in females. Evidence type for each study included a review of study design, risk of bias, inconsistency, indirectness, imprecision, and other considerations.
Recommendation Category A: Recommendation that applies to all persons in an age or risk-based group. Recommendation Category B: Recommendation for individual clinical decision making. Evidence Type 1: Randomized controlled trials, or overwhelming evidence from observational studies. Evidence Type 2: Randomized controlled trials with important limitations, or exceptionally strong evidence from observational studies. Evidence Type 3: Observational studies. Evidence Type 4: Clinical experience and observations, observational studies, or randomized controlled trials with notable limitations. Source: Ahmed F, Temte JL, Campos-Outcalt D, Schünemann HJ; for the ACIP Evidence Based Recommendations Work Group (EBRWG). Methods for developing evidence-based recommendations by the Advisory Committee on Immunization Practices (ACIP) of the U.S. Centers for Disease Control and Prevention (CDC). *Vaccine* 29(49):9171-6, 2011.
Tables for GRADE: HPV Vaccine for Males
Table 1. Quadrivalent HPV Vaccine for Males: Benefits*
Quadrivalent HPV Vaccine for Males: Benefits
Outcome HPV 6-, 11-, 16-, 18- related
No. subjects (# studies)
Incidence in controls
Incidence in vaccinated
Vaccine efficacy (95% CI)
Risk difference per 1000 (95% CI)
Number needed to vaccinatedPopulation: MalesaGenital warts
2798
(1 RCT)
1.99%
0.22%
89.3%
(65.3, 97.9)
-18
(-13, -20)
56Population: MSMbGenital wartsc
402
(1 RCT)
4.33%
0.51%
88.1 (13.9, 99.7)
-38
(-6, -43)
26AIN 1/2/3
402
(1 RCT)
11.5%
2.6%
77.5%
(39.6, 93.3)
-89
(-46, -107)
11AIN 2/3
402
(1 RCT)
6.3%
1.5%
74.9%
(8.8, 95.5)
-48
(-6, -59)
21AIN=anal intraepithelial neoplasia; MSM=men who have sex with men; CI=confidence interval; RCT=randomized controlled trial
Table 1 FootnotesaFollow-up 2.3 yearsbFollow-up 2.6 yearscPersonal Communication, Carlos Sattler MD, August 2011dFrequently reported as number needed to treat or NNT*Among those who received all 3 vaccine doses and were seronegative at day 1 and DNA-negative day 1 through month 7 to the respective HPV type (per protocol population)
Reference: from Package insert. Vaccine efficacy, risk difference, and number needed to vaccinate calculated with GRADEpro software
**Top of Page
Table 2. Quadrivalent HPV vaccine for Males: Evidence Type of Benefits
Quadrivalent HPV vaccine for Males: Evidence Type of Benefits
Outcome
Design
(# studies)
Risk of Bias
Inconsistency
Indirectness
Imprecision
Other Considerations
Evidence TypePopulation: MalesGenital warts
RCT (1)
No serious
No serious
No serious
No serious
None
1Population: MSMGenital warts
RCT (1)
No serious
No serious
No serious
No serious
None
1AIN 1/2/3
RCT (1)
No serious
No serious
No seriousb
No serious
None
1AIN2/3
RCT (1)
No serious
No serious
Yesa,b
No serious
None
2MSM=men who have sex with men; AIN=anal intraepithelial neoplasia; CI=confidence interval; AIN=anal intraepithelial neoplasia; RCT=randomized controlled trial
Table 2 Footnotesa AIN2/3 considered anal precancer lesion (surrogate for anal cancer) downgraded by one level for indirectnessb Evidence in MSM available from clinical trial, no reason to suspect vaccine efficacy for boys aged 11-12 years would differ from that observed in MSM, not downgraded for indirectness
Reference: Package insert Gardasil (quadrivalent human papillomavirus types 6, 11, 16 and 18 HPV)
**Top of Page
Table 3. Quadrivalent HPV Vaccine for Males: Summary Harms from Prelicensure RCTs in Males and Females
Quadrivalent HPV Vaccine for Males: Summary Harms from Prelicensure RCTs in Males and Females
Outcome
No. subjects
(# studies)
Incidence in vaccinated
%
Incidence in controls
%
Summary risk ratio
(95% CI)MalesaSAE
4723 (2 RCTs)
0.4%
0.5%
0.88
(0.38, 2.06)Syncope
4723 (2 RCTs)
0.04%
0.1%
0.50
(0.05, 5.52)VTE
4723 (2 RCTs)
0
0
NEAnaphylaxis
4722 (2 RCTs)
0
0
NEFemalesbSAE
18,893 (4 RCTs)
1.1%
1.1%
0.97
(0.74, 1.27)Syncope
18,893 (4 RCTs)
0.2%
0.2%
0.84
(0.45, 1.55)VTE
18,893 (4 RCTs)
0.03%
0.02%
1.33
(0.30, 5.96)Anaphylaxis
18,893 (4 RCTs)
0
0.01
0.33
(0.01, 8.20)NE= non estimable; VTE=venous thromboembolism; RCT=randomized controlled trial; CI=confidence interval; SAE=serious adverse events: FDA definition including death, hospitalization, life-threatening event, disability, congenital anomaly or birth defect, requiring intervention, or other serious event; VTE = deep vein thrombosis, embolism, thrombophlebitis, thrombosis, or thrombophlebitis, superficial
Table 3 FootnotesaFrom Merck protocols 018 (follow-up 2.5 years), 020 (follow-up 3 years)bFrom Merck protocols 007 (follow-up 3 years), 013 (follow-up 3.7 years), 015 (follow-up 3.7 years), 018 (follow-up 2.5 years)
Summary risk ratio calculated using RevMan software, fixed effects
**Top of Page
Table 4. Quadrivalent HPV Vaccine for Males: Harms from Postlicensure Vaccine Safety Datalink Observational Study in Females
Quadrivalent HPV Vaccine for Males: Harms from Postlicensure Vaccine Safety Datalink Observational Study in Females
Outcome,
age group (yrs)
No. of doses administered
Incidence in vaccinated group
(per 10,000 vaccinations)a
Incidence in comparison group
(per 10,000 vaccinations)
Relative risk (95% CI)cSyncopeb9-18
351,630
17.35
21.72
0.86 (0.72, 1.02)19-26
150,544
11.29
19.31
0.54 (0.42, 0.75)VTEb9-18
292,302
0.274
0.137
1.98d (0.86, 3.94)19-26
176,194
0.624
0.851
0.73 (0.37, 1.31)Anaphylaxise9-26
600,558
0.017
0.015
N/AVTE=venous thromboembolism; CI=confidence interval; N/A=not available
Table 4 Footnotesa For syncope,observed rates presented and risk window was day 0. For VTE, rates were adjusted by site and age. Risk window included days 1-42b Comparison group for syncope was concurrent vaccinated group; for VTE was historical comparison groupc Relative Risk adjusted by site and age; Simulated confidence intervals at the time upper limit was reachedd Confirmed cases of VTE among 9-17 yr olds all had risk factors for VTE (smoking, obesity, oral contraceptive pill use, hypercoaguable disorders)e Comparison group from Bolkhe et al. Risk of anaphylaxis after vaccination of children and adolescents. *Pediatrics* 2003.
Reference: from Gee J, et al. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink. *Vaccine*. 2011
**Top of Page
Table 5. Quadrivalent HPV Vaccine for Males: Harms from Postlicensure Manufacturer Observational Study in Females
Quadrivalent HPV Vaccine for Males: Harms from Postlicensure Manufacturer Observational Study in Females
Outcome
No. of Persons
Incidence in vaccinated group
(per 1,000 person years)
Incidence in comparison group
(per 1,000 person years)
Relative risk
(95% CI)aSyncope
189,629
24.21
4.04
6.00 (3.91,9.21)bVTE
189,629
6.32
4.97
1.27 (0.57,2.86)Allergic reaction or Anaphylactic Shock
189,629
0.16
0.21
0.75 (0.32,1.78)cVTE=venous thromboembolism; CI=confidence interval
VTE includes the following ICD-9 codes: 452 Portal vein thrombosis, 453.0 Budd-Chiari syndrome, 453.1 Thrombophlebitis migrans, 453.2 Embolism & thrombosis of inferior vena cava, 453.3 Embolism & thrombosis of renal vein, 453.4-453.9 Acute and chronic venous embolism & thrombosis of deep or superficial vessels or veins at various sites or unspecified site, V12.51 Personal history of venous thrombosis & embolism.
Outcome is defined as presence of diagnosis code in emergency room or hospital setting in vaccination risk period (day of vaccination for syncope & allergic reaction/anaphylactic shock, & 1-60 days after vaccination for VTE) or in post-vaccination self-comparison (i.e., “control”) period. These codes could represent a new event, a pre-existing condition, a prior history of the condition, a “rule out” diagnosis, miscoding, or a misdiagnosis. A diagnosis code also does not assume that the diagnosis is confirmed. No validation of these codes was performed by medical record review.
Table 5 FootnotesaRelative risk is approximated by odds ratio, obtained from conditional logistic regression;bFor syncope, the relative risk elevation with lower bound CI greater than 1 suggests that syncope diagnosis codes are more likely to occur on day of vaccination than in self-comparison period;cFor allergic reaction/anaphylactic shock, external Safety Review Committee reviewed medical records of females with day 0 diagnosis codes & found no association between diagnosis & vaccination with quadrivalent HPV vaccine.
Reference: ACIP C. Velicer
**Top of Page
Table 6. Quadrivalent HPV vaccine for Males: Evidence Type of Harms
Quadrivalent HPV vaccine for Males: Evidence Type of Harms
Outcome
Design
(# studies, Sex)
Risk of bias
Inconsistency
Indirectness
Imprecision
Other considerations
Evidence typeSAE
RCT (2,M; 4,F)
No serious
No serious
No seriousa
Yesb
None
2VTE
RCT (2,M; 4,F)
No serious
No serious
No seriousa
Yesb
None
2O (2 F)
Yesd
No serious
Yesc
No serious
None
4Syncope
RCT (2,M; 4,F)
No serious
No serious
No seriousa
Yesb
None
2O (2 F)
Yesd
No serious
Yesc
No serious
None
4Anaphylaxis
RCT (2,M; 4,F)
No serious
No serious
No seriousa
Yesb
None
2O (2 F)
Yesd
No serious
Yesc
No serious
None
4VTE=venous thromboembolism; SAE=serious adverse events; RCT=randomized controlled trial; O=observational study
Table 6 FootnotesaFemale data indirect, however male data available, not downgradedbRCTs with small sample size, downgraded one level for imprecisioncStudies conducted in females, downgraded one level for indirectnessdPossible uncontrolled confounding, downgraded one level for risk of bias
Summary for Harm: No evidence of increased risk for anaphylaxis, VTE, or SAE from 5 RCTs in males and females (1 RCT in both males and females), and 2 observational studies in females. One of 7 studies found persons who were vaccinated with HPV4 were more likely to faint on the day they were vaccinated than another period in which vaccine was not administered, likely a result of injection-related syncope.
**Top of Page
Table 7. Summary Evidence Type for Benefits, Harms: Quadrivalent HPV Vaccine for Males
Summary Evidence Type for Benefits, Harms: Quadrivalent HPV Vaccine for Males
Comparison Group
Benefits and Harms
Outcome
Study design
(# studies, sex)
Findings
Evidence type
Overall Evidence typebHPV vaccination versus
no HPV vaccination
Benefits
Genital warts
RCT (1,M)
Decreased risk among vaccinated
1
2AIN1/2/3
RCT (1,M)
Decreased risk among vaccinated
1
2AIN2/3
RCT (1,M)
Decreased risk among vaccinated
2
2Harms
SAE
RCT (2,M; 4,F)
No difference
2
2Syncope
RCT (2,M; 4,F)
No difference
2
2Syncope
O (2, F)
Increased risk among vaccinateda
4
2VTE
RCT (2,M; 4,F)
No difference
2
2VTE
O (2, F)
No difference
4
2Anaphylaxis
RCT (2,M; 4,F)
No difference
2
2Anaphylaxis
O (2, F)
No difference
4
2RCT=randomized controlled trial; O=observational study; F=female; M=male; VTE=venous thromboembolism; SAE=serious adverse events
Table 7 Footnotesa One observational study found persons who were vaccinated with HPV4 were more likely to faint on the day they were vaccinated than another period in which vaccine was not administeredb Overall evidence type 2 based on evidence from the strongest study design for critical harms and benefits
**Top of Page
Table 8. Considerations for Formulating Recommendations: Quadrivalent HPV Vaccine for Males
Considerations for Formulating Recommendations: Quadrivalent HPV Vaccine for Males
Key factors
CommentsBalance between benefits and harms
Benefits are greater than potential harmsEvidence type for benefits and harms
Evidence Type 2 Benefit
Evidence Type 2 Harm RCT
Evidence Type 4 Harm OValue
High value placed by ACIP HPV Work Group on prevention of cancer in malesCost-effectiveness
HPV4 is most cost-effective if all HPV associated outcomes prevented, vaccine cost lower than current price, female coverage low (such as 30% 3-dose coverage at age 12 years)RCT=randomized controlled trial; O=observational study
Table 8 FootnotesSummary for Benefits and Harms: Benefits are greater than potential harms and overall evidence type is 2. There is high value placed on prevention of cancer in males. Quadrivalent HPV vaccine is most cost-effective if all HPV associated outcomes are prevented, vaccine cost is lower than current price, or female coverage is low. Recommendation for routine vaccination of males aged 11 or 12 years with HPV4 administered as a 3-dose series (*recommendation category A; evidence type 2*)
References
C Velicer. ACIP Presentation. Post-licensure Safety Study of Quadrivalent Human Papillomavirus Vaccine among 189,629 Females Presented at October 2011 ACIP Meeting.
Ahmed F, Temte JL, Campos-Outcalt D, Schünemann HJ, for the ACIP Evidence Based Recommendations Work Group (EBRWG). Methods for developing evidence-based recommendations by the ACIP of the CDC. *Vaccine* 2011;29(49):9171-76.
Bohlke K, Davis RL, DeStefano F, Marcy SM, Braun MM, Thompson RS; Vaccine Safety Datalink Team. Epidemiology of anaphylaxis among children and adolescents enrolled in a health maintenance organization. *J Allergy Clin Immunol* 2004;113:536-42.
Chesson HW, Ekwueme DU, Saraiya M, Dunne EF, Markowitz LE. The cost-effectiveness of male HPV vaccination in the United States. *Vaccine* 2011;29:8443-50.
Food and Drug Administration, Product approval information – licensing action, package insert: Gardasil (quadrivalent human papillomavirus types 6, 11, 16 and 18 HPV), Merck & Co. Whitehouse Station, NJ: Food and Drug Administration; 2009.
Gee J, Naleway A, Shui I,et al. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink. *Vaccine* 2011;29:8279-84.
Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. *N Engl J Med* 2011;364:401-11.
Palefsky JM, Giuliano AR, Goldstone S, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. *N Engl J Med* 2011;365:1576-85.**Top of Page
					View Page In:PDF [1M]		
					
							Last Reviewed:  April 15, 2016						Source: 	National Center for Immunization and Respiratory Diseases
					Facebook
        Twitter
        LinkedIn
        Syndicate homeACIP Home
Meeting Information
Committee Informationplus icon
Role of the ACIP in CDC’s Vaccine Recommendations
Charter
Economics Studies
Committee Membersplus icon
ACIP Membership Roster
Apply for ACIP Membership
Work Groupsplus icon
VaST Reportsplus icon
June 28, 2021
May 24, 2021
May 17, 2021
March 29, 2021
Recommendationsplus icon
Shared Clinical Decision-Making Recommendations
Evidence Based Recommendationsplus icon
About GRADE
Grade Evidence Tables
Evidence to Recommendations Frameworks Vaccines & ImmunizationsImmunization SchedulesVFC ResolutionsVaccine Information Statements (VISs)
  1600 Clifton Road, N.E., Mailstop A27
Atlanta, GA 30329-4027acip@cdc.gov


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue